|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We show for the first time that low E2F1 levels in BRAF<sup>V600E</sup> melanomas are associated with lymph node metastasis.
|
31124185 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
E2F1 CNV was measured in genomic DNA isolated from blood of 552 patients diagnosed with melanoma and 520 healthy subjects using TaqMan Copy Number Assays.
|
31142321 |
2019 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Reduced RB abundance, in turn, impairs E2F1 transcriptional inhibition, leading to increased peptidyl-prolyl cis-trans isomerase never-in-mitosis A (NIMA)-interacting 1 (PIN1) levels, human keratinocyte neoplastic cell transformation, and melanoma tumorigenesis via enhanced rapidly accelerated fibrosarcoma 1(RAF1)-MEK-ERK signaling pathway activation.
|
29750576 |
2018 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using CRISPR-Cas9 to engineer a cellular model of melanoma initiation from primary human melanocytes, we discovered that a lineage-restricted transcription factor, BRN2, is downstream of CDKN2A and directly regulated by E2F1.
|
29990501 |
2018 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, our data demonstrate the pro-tumorigenic role of KLF4 in melanoma and uncover a novel ERK1/2-E2F1-KLF4 axis.
|
28068326 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data show that activation of HH signaling enhances proliferation in presence of E2F1 and promotes apoptosis in its absence or upon CDK1 inhibition, suggesting that E2F1/iASPP dictates the outcome of HH signaling in melanoma.
|
26024388 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The transcription factor E2F1 is crucial for melanoma progression through poorly understood mechanisms.
|
25341426 |
2014 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
By avoiding MTX exportation, we observed that the E2F1 apoptotic pathway is functional in melanoma, and its induction activates p73 and apoptosis protease-activating factor 1 following a p53-autonomous proapoptotic signaling event.
|
23814494 |
2013 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent evidence, however, showed that E2F1, which is aberrantly expressed in advanced malignant melanomas together with antagonistic p73 family members, drives cancer progression.
|
22871739 |
2012 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In fact, inactivation of NF-kappaB is associated with melanoma cell apoptosis induced by E2F-1 and doxorubicin, providing a link between the NF-kappaB signaling pathway and the chemosensitivity of melanoma cells after this treatment.
|
19565909 |
2009 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our study not only elucidated that ASK/Dbf4, a novel cell survival gene in melanoma was transcriptionally regulated by E2F1, but also that the induction of ASK/Dbf4 was refractory to UVB exposure suggesting that its upregulation was not an early event in melanomagenesis.
|
18503552 |
2008 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
In summary, our study not only elucidated that ASK/Dbf4, a novel cell survival gene in melanoma was transcriptionally regulated by E2F1, but also that the induction of ASK/Dbf4 was refractory to UVB exposure suggesting that its upregulation was not an early event in melanomagenesis.
|
18503552 |
2008 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our studies strongly demonstrated that E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation.
|
17263886 |
2007 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
E2F1 may cooperate with alterations in the MAPK or Rb pathways in the promotion of proliferation in many or most types of melanoma and may become a target for therapeutic intervention.
|
16775429 |
2006 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Inhibition of E2F1 expression with RNAi also reduced melanoma cell growth.
|
16481740 |
2006 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
E2F1 may cooperate with alterations in the MAPK or Rb pathways in the promotion of proliferation in many or most types of melanoma and may become a target for therapeutic intervention.
|
16775429 |
2006 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combination of E2F-1 gene therapy and chemotherapy produces a synergistic effect on melanoma cell apoptosis.
|
16827129 |
2006 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, Western blot analysis demonstrated increased E2F1 protein levels in 8 out of 9 melanoma cell lines relative to normal melanocytes.
|
16481740 |
2006 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Our findings have identified, for the first time, novel molecular targets and pathways that led to apoptosis in melanoma cells when Ad-E2F-1 was combined with doxorubicin.
|
16827129 |
2006 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Our findings have identified, for the first time, novel molecular targets and pathways that led to apoptosis in melanoma cells when Ad-E2F-1 was combined with doxorubicin.
|
16827129 |
2006 |
|
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
These results indicate that deregulation of E2F1 may be a key factor in eugenol-mediated melanoma growth inhibition both in vitro and in vivo.
|
15574415 |
2005 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
These results indicate that deregulation of E2F1 may be a key factor in eugenol-mediated melanoma growth inhibition both in vitro and in vivo.
|
15574415 |
2005 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that deregulation of E2F1 may be a key factor in eugenol-mediated melanoma growth inhibition both in vitro and in vivo.
|
15574415 |
2005 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PKR can either be up-regulated through direct induction by the transcription factor E2F-1, or it can be activated through direct protein-protein interactions with the melanoma differentiation-associated gene-7 (MDA7, IL-24).
|
15174900 |
2004 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Two human melanoma cell lines, SK-MEL-28 (wild-type p53) and SK-MEL-2 (mutant p53), were treated by mock infection, infection with a control vector expressing the beta-galactosidase gene (Ad5CMV-LacZ), or infection with a vector expressing E2F-1 (Ad5CMV-E2F-1) at a multiplicity of infection of 100.
|
10570427 |
1999 |